Recursion PharmaceuticalsRXRX
RXRX
About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Employees: 500
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
102% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 53
0% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 6 (+0) [Q3]
2% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 46
2% less funds holding
Funds holding: 268 [Q2] → 263 (-5) [Q3]
10% less capital invested
Capital invested by funds: $1.91B [Q2] → $1.73B (-$183M) [Q3]
17.34% less ownership
Funds ownership: 110.7% [Q2] → 93.35% (-17.34%) [Q3]
42% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $19.8M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
53%
upside
Avg. target
$10.50
61%
upside
High target
$11
68%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Keybanc Scott Schoenhaus 17% 1-year accuracy 6 / 36 met price target | 53%upside $10 | Overweight Maintained | 8 Jan 2025 |
Needham Gil Blum 16% 1-year accuracy 28 / 170 met price target | 68%upside $11 | Buy Reiterated | 11 Dec 2024 |
Financial journalist opinion
Based on 5 articles about RXRX published over the past 30 days
Positive
The Motley Fool
3 days ago
Is Recursion Pharmaceuticals Stock a Buy?
Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (RXRX -0.31%) could be positioned to ride the ongoing wave of hype to great heights. Between its AI-first approach to designing new drugs and its positioning as a valuable collaborator for other companies, the company is worth paying attention to at a minimum.
Negative
Zacks Investment Research
5 days ago
Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $6.42, marking a +1.58% move from the previous day.
Positive
Zacks Investment Research
1 week ago
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?
The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
1 week ago
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
Salt Lake City, UT, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has cleared a clinical trial application (CTA) for a Phase 1 clinical trial of REC-3565, a potential best-in-class MALT1 inhibitor for B-cell malignancies. For REC-3565, the total addressable population could include a range of hematological indications, with approximately 41,000 relapsed and/or refractory (R/R) patients with chronic lymphocytic leukemia (CLL) and B-cell lymphomas in the US+EU5 annually.
Neutral
GlobeNewsWire
2 weeks ago
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
Salt Lake City, UT, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announces that co-founder and CEO Chris Gibson, PhD will present at the upcoming 43rd Annual JP Morgan Healthcare Conference in San Francisco.
Positive
The Motley Fool
1 month ago
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time.
Positive
The Motley Fool
1 month ago
1 Artificial Intelligence (AI) Stock That Could Soar in 2025
The artificial intelligence (AI) field has been grabbing many headlines on Wall Street in the past two years. Will this trend continue in 2025?
Neutral
GlobeNewsWire
1 month ago
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that on December 19, 2024, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 7,952,836 shares of its class A common stock in the aggregate to 230 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with a subsidiary of Recursion in connection with Recursion's acquisition of Exscientia plc and pursuant to Nasdaq Listing Rule 5635(c)(4).
Positive
Seeking Alpha
1 month ago
Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The recent acquisition of Exscientia strengthens Recursion's pipeline and partnerships, potentially delivering up to $20 billion in milestone payments from collaborations with pharma giants. Despite unimpressive clinical trial results, the company's innovative platform and strategic partnerships justify a "Buy" rating for long-term, high-risk-tolerant investors.
Neutral
GlobeNewsWire
1 month ago
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors.
Charts implemented using Lightweight Charts™